Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, plans to begin testing ENV-294, its leading drug candidate developed to treat atopic ...

Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic, ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Odell Beckham Jr. first noticed flakes throughout his iconic beard and hairline in his 20s; today, for the first time he is ...

Arcutis Biotherapeutics is going long with the latest push for its seborrheic dermatitis treatment Zoryve. | Arcutis ...

Healio Dermatology will be reporting live at South Beach Symposium 2025 from Feb. 6 to 8 in Miami Beach, Florida. The 23rd ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD ... Th2-mediated skin inflammation – a mechanism that the drug shares with Sanofi and ...

Rubbing the skin vigorously leaves a mark and sometimes complicates the injury, as in some dermatitis cases. Now scientists ...

New Understanding of the Gut Immune System May Hold Promise for Crohn's Disease Patients Mar. 15, 2024 — Scientists uncovered an overlooked mechanism ... Adults with atopic dermatitis (AD ...

Importance: Disease models for atopic dermatitis (AD) have primarily focused on understanding underlying environmental, immunologic, and genetic etiologies. However, the role of metabolic mechanisms ...